Insmed
ISIN US4576693075
|WKN A1JJA3
Overview
Description
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 12,773.17 m |
| EPS, EUR | -5.16 |
| P/B ratio | 45.26 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 336.24 m |
| Net income, EUR | -844.76 m |
| Profit margin | -251.24% |
What ETF is Insmed in?
There are 35 ETFs which contain Insmed. All of these ETFs are listed in the table below. The ETF with the largest weighting of Insmed is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
